NYSE - Delayed Quote
USD
GSK plc (GSK)
49.89
-0.98
(-1.93%)
At close: September 4 at 4:00:02 PM EDT
50.74
+0.85
(+1.70%)
After hours: September 4 at 7:59:42 PM EDT
Trade GSK on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for GSK
What's happening with GSK?
Powered by Yahoo ScoutGSK has made significant strides in its drug pipeline, notably receiving its first global approval for a hepatitis B treatment and advancing its mRNA flu vaccine into late-stage trials. These developments highlight potential for substantial revenue growth, with forecasts suggesting a £2 billion opportunityfor hepatitis B if market adoption is successful.
Powered by Yahoo Scout
- Previous Close
50.87 - Open
49.70 - Bid 49.80 x 80000
- Ask 50.06 x 50000
- Day's Range
49.66 - 50.06 - 52 Week Range
39.29 - 61.70 - Volume
2,284,805 - Avg. Volume
3,826,838 - Market Cap (intraday)
99.92B - Beta (5Y Monthly) 0.29
- PE Ratio (TTM)
15.69 - EPS (TTM)
3.18 - Earnings Date (est.) Oct 28, 2026
- Forward Dividend & Yield 1.82 (3.64%)
- Ex-Dividend Date Aug 14, 2026
- 1y Target Est
58.58
Recent News
View More
Performance Overview
Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
GSK
4.42%
FTSE 100 (^FTSE)
9.06%
1-Year Return
GSK
30.41%
FTSE 100 (^FTSE)
17.51%
3-Year Return
GSK
60.07%
FTSE 100 (^FTSE)
45.33%
5-Year Return
GSK
46.79%
FTSE 100 (^FTSE)
51.73%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 9/3/2026
-
Market Cap
100.84B
-
Enterprise Value
121.24B
-
Trailing P/E
15.98
-
Forward P/E
19.19
-
PEG Ratio (5yr expected)
95.97
-
Price/Sales (ttm)
2.32
-
Price/Book (mrq)
4.27
-
Enterprise Value/Revenue
2.71
-
Enterprise Value/EBITDA
9.29
Financial Highlights
Profitability and Income Statement
-
Profit Margin
14.52%
-
Return on Assets (ttm)
10.01%
-
Return on Equity (ttm)
33.38%
-
Revenue (ttm)
33.2B
-
Net Income Avi to Common (ttm)
4.82B
-
Diluted EPS (ttm)
3.18
Balance Sheet and Cash Flow
-
Total Cash (mrq)
3.11B
-
Total Debt/Equity (mrq)
106.50%
-
Levered Free Cash Flow (ttm)
3.48B
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View More-
Low P/E ratio and high yield
GSK plc, based in Brentford, UK, is a global healthcare company engaged in the discovery, development, manufacture, and marketing of pharmaceutical products. The company's leading products include treatments for asthma and COPD; treatments for HIV infection; and a range of vaccines. The company has active research and development programs in immuno-inflammation, neuroscience, metabolic pathways, ophthalmology, respiratory and infectious diseases, and biopharmaceuticals.
RatingPrice Target -
The major indices are lower at midday. Bond yields continue to rise over
The major indices are lower at midday. Bond yields continue to rise over worries that interest rates are heading even higher. Oil prices are also climbing again. Crude oil is at $88 per barrel. The yield on the 10-year note is at 4.77%.
-
GSK Set up for Steady Long-Term Growth As Portfolio and Pipeline Develop
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
RatingPrice Target -
GSK Earnings: Another Strong Quarter for Vaccines, Three-Year Restructuring Program Announced
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
RatingPrice Target
